Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Curr Pharm Des. 2012;18(22):3215–3221. doi: 10.2174/1381612811209023215

Figure 1. Impact of cytogenetic risk category on HCT outcome in patients with de novo and with secondary MDS/tAML.

Figure 1

A) Probability of relapse, B) Probability of relapse-free survival, based on cytogenetic risk as defined by IPSS [75]. This research was originally published in Blood. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. C. Chang, B.E. Storer, B.L. Scott, E.M. Bryant, H.M. Shulman, M.E. Flowers, B.M. Sandmaier, R.P. Witherspoon, R.A. Nash, J.E. Sanders, A. Bedalov, J.A. Hansen, B.E. Clurman, R. Storb, F.R. Appelbaum, H. Joachim Deeg, Blood 2007; 110: 1379–1387. © the American Society of Hematology.